Tech M&A Decline, Gilead's Acquisition of Arcellx, and Merck's Pharma Division Split

The technology sector is experiencing a downturn in mergers and acquisitions, with activity slowing significantly. Bloomberg posted on X, highlighting the recent developments in the industry. In a notable transaction, Gilead Sciences has reached an agreement to acquire Arcellx, a move that underscores its strategic focus on expanding its portfolio in the biotech field. Meanwhile, Merck has announced plans to separate its pharmaceutical division, a strategic decision aimed at enhancing operational efficiency and focusing on core business areas. These developments reflect broader trends in the healthcare and technology sectors, where companies are reevaluating their strategies amid changing market conditions.